Poussard M, Boichut M, Belakri I, Biichle S, Fredon M, Cael B, Roussel X, Renosi F, Van Moer K, Janji B, Monnien F, Boichut C, Boidot R, Ndao B, Adotevi O, Garnache-Ottou F, Watkins K, Lakshmikanthan S, Angelot-Delettre F

Haematologica. 2026 02 5;:

Circulating transcriptome analysis finds gene signatures and immune cell activation and abundance predict response to immunotherapy in bladder cancer.

Chevrier S, Richard C, Adotévi O, Ayyoub M, Chaput N, Damotte D, Ghiringhelli F, Hacein-Bey-Abina S, Tartour E, Zitvogel L, Marabelle A, Boidot R

Clin Cancer Res. 2026 01 13;:

In synergy with interferon-gamma, interleukin-17 activates vascular stromal cells towards a pro-inflammatory profile in giant cell arteritis.

Greigert H, Ramon A, Cladiere C, Lamarthée B, Richard C, Ciudad M, Varin A, Herrmann N, Praliaud R, Brenac G, Razanamahery J, Arnould L, Gabrielle PH, Creuzot-Garcher C, Tarris G, Martin L, Audia S, Boidot R, Bonnotte B, Samson M

Arthritis Rheumatol. 2026 01 12;:

Combined effects of mesenchymal stromal cells and antibiotic therapy on Enterobacter ventilator-associated pneumonia in rabbits.

Jacquier M, Laroye C, Bensoussan D, Nguyen S, Croisier D, Richard C, Boidot R, Masson D, Charles PE, Blot M

Respir Res. 2026 01 7;:

Mature CD209CD83CCR7 dendritic cells infiltrate the arterial wall in giant cell arteritis and derive from in-situ monocyte differentiation.

Ramon A, Greigert H, Lamarthée B, Richard C, Varin A, Cladière C, Genet C, Ciudad M, Klopfenstein N, Praliaud R, Brenac G, Tarris G, Martin L, Arnould L, Gabrielle PH, Garcher CC, Ornetti P, Audia S, Boidot R, Maillefert JF, Bonnotte B, Samson M

Sci Rep. 2025 10 17;15(1):36419

Targeted oral delivery of microencapsulated TNF-α siRNA in an experimental model of colitis.

Stalder T, Moulari B, Cornu R, Chatelain J, Koenig N, Hassan A, Chretien C, Boidot R, Richard C, Pellequer Y, Jurin F, Pierre H, Martin H, Béduneau A

Drug Deliv Transl Res. 2025 08 6;:

Venetoclax in the Therapeutic Strategy for BPDCN Management.

Poussard M, Fredon M, Belakri I, Biichle S, Renosi F, Seffar E, Boichut M, Boidot R, Bôle-Richard E, Bonnefoy F, Kroemer M, Bonnot-Perrin S, Saas P, Adotévi O, Garnache-Ottou F, Angelot-Delettre F

EJHaem. 2025 08;6(4):e70070

Fat taste sensitivity in women with obesity: transcriptomic analysis of fungiform papillae before and after bariatric surgery.

Bernard A, Richard C, Radoi L, Boidot R, Ledoux S, Besnard P

Obesity (Silver Spring). 2025 06 22;:

New leads to enhance tagraxofusp efficacy in pDC-AML.

Boichut M, Poussard M, Roussel X, Belakri I, Biichlé S, Fredon M, Renosi F, Boidot R, Adotevi O, Brooks C, Garnache-Ottou F, Angelot Delettre F

Blood Neoplasia. 2025 05;2(2):100066

The intrinsic expression of NLRP3 in Th17 cells promotes their protumor activity and conversion into Tregs.

Accogli T, Hibos C, Milian L, Geindreau M, Richard C, Humblin E, Mary R, Chevrier S, Jacquin E, Bernard A, Chalmin F, Paul C, Ryffel B, Apetoh L, Boidot R, Bruchard M, Ghiringhelli F, Vegran F

Cell Mol Immunol. 2025 04 7;:

Distinct immune responses to proton and photon radiotherapy: implications for anti-PD-L1 combination therapy in colorectal cancer.

Burckel H, Nicol A, Mura C, Rousseau M, Bou-Gharios J, Froidurot L, Richard C, Morgand V, Laurent PA, Limagne E, Boidot R, Noël G, Mirjolet C

J Transl Med. 2025 03 23;23(1):360

Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption.

Lopez M, Spehner L, André F, Viot J, Seffar E, Marguier A, Curtit E, Meynard G, Dobi E, Ladoire S, Boidot R, Loyon R, Derangere V, Bidard FC, Borg C, Mansi L, Kroemer M

Breast Cancer Res. 2025 02 7;27(1):19

Decoding mutational signatures in breast cancer: Insights from a multi-cohort study.

Betz M, Witz A, Dardare J, Michel C, Massard V, Boidot R, Gilson P, Merlin JL, Harlé A

Transl Oncol. 2025 02 4;53:102315

Acidosis overrides molecular heterogeneity to shape therapeutically targetable metabolic phenotypes in colon cancers.

Richiardone E, Giolito MV, Al Roumi R, Ambroise J, Boidot R, Drotleff B, Ghesquière B, Lupo B, Trusolino L, Bardelli A, Arena S, Feron O, Corbet C

Cancer Lett. 2025 02 1;:217512

PPARα-mediated lipid metabolism reprogramming supports anti-EGFR therapy resistance in head and neck squamous cell carcinoma.

Van den Bossche V, Vignau J, Vigneron E, Rizzi I, Zaryouh H, Wouters A, Ambroise J, Van Laere S, Beyaert S, Helaers R, van Marcke C, Mignion L, Lepicard EY, Jordan BF, Guilbaud C, Lowyck O, Dahou H, Mendola A, Desgres M, Aubert L, Gerin I, Bommer GT, Boidot R, Vermonden P, Warnant A, Larondelle Y, Machiels JP, Feron O, Schmitz S, Corbet C

Nat Commun. 2025 02 1;16(1):1237

Nanopore adaptive sampling accurately detects nucleotide variants and improves the characterization of large-scale rearrangement for the diagnosis of cancer predisposition.

Chevrier S, Richard C, Mille M, Bertrand D, Boidot R

Clin Transl Med. 2025 01;15(1):e70138

CD40 agonist on patient-derived xenograft mice for the treatment of B-cell acute lymphoblastic leukemia.

Bellaye PS, Georgievski A, Ballerini P, Bouslama B, Richard C, Boidot R, Chevreux G, Legros V, Guy J, Racine J, Collin B, Garrido C, Quéré R

Clin Cancer Res. 2024 11 14;:

The DAV132 colon-targeted adsorbent does not interfere with plasma concentrations of antibiotics but prevents antibiotic-related dysbiosis: a randomized phase I trial in healthy volunteers.

Messaoudene M, Ferreira S, Saint-Lu N, Ponce M, Truntzer C, Boidot R, Le Bescop C, Loppinet T, Corbel T, Féger C, Bertrand K, Elkrief A, Isaksen M, Vitry F, Sablier-Gallis F, Andremont A, Bod L, Ghiringhelli F, de Gunzburg J, Routy B

Nat Commun. 2024 09 15;15(1):8083

Targeting mTOR signaling for the treatment of intrahepatic cholangiocarcinoma with TSC1/ARID1A mutations: a case report with an unexpected response.

Daugan C, Boidot R, Ghiringhelli F, Borg C, Vienot A

Ther Adv Med Oncol. 2024 09 13;16:17588359241271793

Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, co-mutated metastatic NSCLC.

Roussot N, Thibaudin M, Fumet JD, Daumoine S, Hampe L, Rébé C, Limagne E, Lagrange A, Herreros V, Lecuelle J, Mananet H, Ilie A, Rageot D, Boidot R, Goussot V, Comte A, Jacob P, Beltjens F, Bergeron A, Charon-Barra C, Arnould L, Derangère V, Ladoire S, Truntzer C, Ghiringhelli F

Front Immunol. 2024 08 7;15:1437961

MCT1-dependent lactate recycling is a metabolic vulnerability in colorectal cancer cells upon acquired resistance to anti-EGFR targeted therapy.

Richiardone E, Al Roumi R, Lardinois F, Giolito MV, Ambroise J, Boidot R, Drotleff B, Ghesquière B, Bellahcène A, Bardelli A, Arena S, Corbet C

Cancer Lett. 2024 07 2;:217091

Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells.

Vidana Gamage HE, Albright ST, Smith AJ, Farmer R, Shahoei SH, Wang Y, Fink EC, Jacquin E, Weisser E, Bautista RO, Henn MA, Schane CP, Nelczyk AT, Ma L, Gupta AD, Bendre SV, Nguyen T, Tiwari S, Krawczynska N, He S, Tjoanda E, Chen H, Sverdlov M, Gann PH, Boidot R, Vegran F, Fanning SW, Apet L, Hergenrother PJ, Nelson ER

Cancer Lett. 2024 06 27;:217086

NR0B2 re-educates myeloid immune cells to reduce regulatory T cell expansion and progression of breast and other solid tumors.

Vidana Gamage HE, Shahoei SH, Wang Y, Jacquin E, Weisser E, Bautista RO, Henn MA, Schane CP, Nelczyk AT, Ma L, Das Gupta A, Bendre SV, Nguyen T, Tiwari S, Tjoanda E, Krawczynska N, He S, Albright ST, Farmer R, Smith AJ, Fink EC, Chen H, Sverdlov M, Gann PH, Boidot R, Vegran F, Fanning SW, Hergenrother PJ, Apetoh L, Nelson ER

Cancer Lett. 2024 06 20;:217042

Impact of scFv on functionality and safety of third generation CD123 CAR T cells.

Fredon M, Poussard M, Biichlé S, Bonnefoy F, Mantion CF, Seffar E, Renosi F, Bôle-Richard E, Boidot R, Chevrier S, Anna F, Loustau M, Caumartin J, Gonçalves-Venturelli M, Robinet E, Saas P, Deconinck E, Daguindau E, Roussel X, Godet Y, Adotévi O, Angelot-Delettre F, Galaine J, Garnache-Ottou F

Cancer Immunol Res. 2024 05 31;:

HER2-Low Luminal Breast Carcinoma Is Not a Homogenous Clinicopathological and Molecular Entity.

André C, Bertaut A, Ladoire S, Desmoulins I, Jankowski C, Beltjens F, Charon-Barra C, Bergeron A, Richard C, Boidot R, Arnould L

Cancers (Basel). 2024 05 25;16(11):

Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer.

Boidot R, Blum MGB, Wissler MP, Gottin C, Ruzicka J, Chevrier S, Delhomme TM, Audoux J, Jeanniard A, Just PA, Harter P, Pignata S, González-Martin A, Marth C, Mäenpää J, Colombo N, Vergote I, Fujiwara K, Duforet-Frebourg N, Bertrand D, Philippe N, Ray-Coquard I, Pujade-Lauraine E,

Eur J Cancer. 2024 03 2;202:113978

Tumor acidosis-induced DNA damage response and tetraploidy enhance sensitivity to ATM and ATR inhibitors.

Aubert L, Bastien E, Renoult O, Guilbaud C, Özkan K, Brusa D, Bouzin C, Richiardone E, Richard C, Boidot R, Léonard D, Corbet C, Feron O

EMBO Rep. 2024 02 16;:

Advancing precision oncology through systematic germline and tumor genetic analysis: The oncogenetic point of view on findings from a prospective multicenter clinical trial of 666 patients.

Mazel B, Bertolone G, Baurand A, Cosset E, Sawka C, Robert M, Gautier E, Lançon A, Réda M, Favier L, Dérangère V, Richard C, Binquet C, Boidot R, Goussot V, Albuisson J, Ghiringhelli F, Faivre L, Nambot S

Cancer Med. 2023 09 11;:

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.

Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derangère V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F

Nat Med. 2023 08 10;:

Regulatory T-cell dysfunctions are associated with increase in tumor necrosis factor α in autoimmune hemolytic anemia and participate in Th17 polarization.

Ciudad M, Ouandji S, Lamarthée B, Cladière C, Ghesquière T, Nivet M, Thébault M, Boidot R, Soudry-Faure A, Chevrier S, Richard C, Maillet T, Maurier F, Greigert H, Genet C, Ramon A, Trad M, Predan V, Saas P, Samson M, Bonnotte B, Audia S

Haematologica. 2023 08 3;:

Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes.

Dalens L, Niogret J, Richard C, Chevrier S, Foucher P, Coudert B, Lagrange A, Favier L, Westeel V, Kim S, Adotevi O, Chapusot C, Martin L, Arnould L, Kaderbhai CG, Boidot R

Mol Cancer. 2023 07 29;22(1):120

Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency.

Schmitt A, Royer B, Boidot R, Berthier J, Ghiringhelli F

Front Oncol. 2023 06 20;13:1187052

GTN Enhances Antitumor Effects of Doxorubicin in TNBC by Targeting the Immunosuppressive Activity of PMN-MDSC.

Mabrouk N, Racoeur C, Shan J, Massot A, Ghione S, Privat M, Dondaine L, Ballot E, Truntzer C, Boidot R, Hermetet F, Derangère V, Bruchard M, Végran F, Chouchane L, Ghiringhelli F, Bettaieb A, Paul C

Cancers (Basel). 2023 06 9;15(12):

Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type.

Dalens L, Lecuelle J, Favier L, Fraisse C, Lagrange A, Kaderbhai C, Boidot R, Chevrier S, Mananet H, Derangère V, Truntzer C, Ghiringhelli F

Int J Mol Sci. 2023 04 20;24(8):

PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy.

Tharin Z, Richard C, Derangère V, Ilie A, Arnould L, Ghiringhelli F, Boidot R, Ladoire S

Sci Rep. 2023 03 18;13(1):4467

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer.

Galland L, Roussot N, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Reda M, Albuisson J, Arnould L, Boidot R, Truntzer C, Ghiringhelli F, Ladoire S

Cancers (Basel). 2023 02 18;15(4):

The "extreme phenotype approach" applied to male breast cancer allows the identification of rare variants of ATR as potential breast cancer susceptibility alleles.

Chevarin M, Alcantara D, Albuisson J, Collonge-Rame MA, Populaire C, Selmani Z, Baurand A, Sawka C, Bertolone G, Callier P, Duffourd Y, Jonveaux P, Bignon YJ, Coupier I, Cornelis F, Cordier C, Mozelle-Nivoix M, Rivière JB, Kuentz P, Thauvin C, Boidot R, Ghiringhelli F, O'Driscoll M, Faivre L, Nambot S

Oncotarget. 2023 02 7;14:111-125

Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.

Ballot E, Galland L, Mananet H, Boidot R, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S

Breast Cancer Res. 2022 11 18;24(1):80

Detection of relevant pharmacogenetic information through exome sequencing in oncology.

Verdez S, Albuisson J, Duffourd Y, Boidot R, Reda M, Thauvin-Robinet C, Fumet JD, Ladoire S, Nambot S, Callier P, Faivre L, Ghiringhelli F, Picard N

Pharmacogenomics. 2022 08 31;:

Uncommon EGFR mutations in lung carcinoma: features and treatment outcomes in a retrospective French cohort.

Tankere P, Boidot R, Bonniaud P, Zouak A, Foucher P, Milliere A, Bertaut A, Favier L, Lagrange A, Ghiringhelli F, Kaderbhai CG, Fraisse C

J Thorac Dis. 2022 06;14(6):2034-2044

Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects.

Mary R, Chalmin F, Accogli T, Bruchard M, Hibos C, Melin J, Truntzer C, Limagne E, Derangère V, Thibaudin M, Humblin E, Boidot R, Chevrier S, Arnould L, Richard C, Klopfenstein Q, Bernard A, Urade Y, Harker JA, Apetoh L, Ghiringhelli F, Végran F

Cancer Immunol Res. 2022 05 25;:OF1-OF17

Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.

Chevrier S, Brasselet A, Carnet M, Chevriaux A, Gibeaud A, Jourdain M, Mananet H, Truntzer C, Beltjens F, Charon-Barra C, Arnould L, Albuisson J, Comte A, Derangère V, Goussot V, Boidot R

Int J Mol Med. 2022 May;49(5):

Alternative Splicing in Cancer and Immune Cells.

Bernard A, Boidot R, Végran F

Cancers (Basel). 2022 Mar 28;14(7):

Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series.

Niogret J, Derangère V, Richard C, Nuttin L, Ghiringhelli F, Favier L, Lefevre LB, Bergeron A, Arnould L, Boidot R

Int J Mol Sci. 2022 Mar 19;23(6):

Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing.

Galland L, Ballot E, Mananet H, Boidot R, Lecuelle J, Albuisson J, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S

NPJ Breast Cancer. 2022 Mar 4;8(1):28

MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer.

Lecuelle J, Favier L, Fraisse C, Lagrange A, Kaderbhai C, Boidot R, Chevrier S, Joubert P, Routy B, Truntzer C, Ghiringhelli F

J Immunother Cancer. 2022 Mar;10(3):

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.

Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, Mazieres J, Audigier-Valette C, Moro-Sibilot D, Goldwasser F, Silva CAC, Terrisse S, Bonvalet M, Scherpereel A, Pegliasco H, Richard C, Ghiringhelli F, Elkrief A, Desilets A, Blanc-Durand F, Cumbo F, Blanco A, Boidot R, Chevrier S, Daillère R, Kroemer G, Alla L, Pons N, Le Chatelier E, Galleron N, Roume H, Dubuisson A, Bouchard N, Messaoudene M, Drubay D, Deutsch E, Barlesi F, Planchard D, Segata N, Martinez S, Zitvogel L, Soria JC, Besse B

Nat Med. 2022 Feb 3;:

Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses.

Bruchard M, Geindreau M, Perrichet A, Truntzer C, Ballot E, Boidot R, Racoeur C, Barsac E, Chalmin F, Hibos C, Baranek T, Paget C, Ryffel B, Rébé C, Paul C, Végran F, Ghiringhelli F

Nat Immunol. 2022 Feb;23(2):262-274

A natural polyphenol exerts antitumor activity and circumvents anti-PD-1 resistance through effects on the gut microbiota.

Messaoudene M, Pidgeon R, Richard C, Ponce M, Diop K, Benlaifaoui M, Nolin-Lapalme A, Cauchois F, Malo J, Belkaid W, Isnard S, Fradet Y, Dridi L, Velin D, Oster P, Raoult D, Ghiringhelli F, Boidot R, Chevrier S, Kysela DT, Brun YV, Falcone EL, Pilon G, Plaza Onate F, Gitton-Quent O, Le Chatelier E, Durand S, Kroemer G, Elkrief A, Marette A, Castagner B, Routy B

Cancer Discov. 2022 Jan 14;:

OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients.

Vachenc S, Gobbo J, Moujarrebe SE, Desmoulins I, Gilabert M, Beau-Faller M, Mitry E, Girard N, Bertaut A, Dusetti N, Iovanna JL, Yousfi R, Pierrat F, Bruno R, Cueff A, Boidot R, Genne P

BMC Cancer. 2022 Jan 6;22(1):41

CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of T1 and T9 cells.

Benoit-Lizon I, Jacquin E, Rivera Vargas T, Richard C, Roussey A, Dal Zuffo L, Martin T, Melis A, Vinokurova D, Shahoei SH, Baeza Garcia A, Pignol C, Giorgiutti S, Carapito R, Boidot R, Végran F, Flavell RA, Ryffel B, Nelson ER, Soulas-Sprauel P, Lawrence T, Apetoh L

J Immunother Cancer. 2022 01;10(1):

Is There a Role for Large Exome Sequencing in the Management of Metastatic Non-Small Cell Lung Cancer: A Brief Report of Real Life.

Dalens L, Niogret J, Kaderbhai CG, Boidot R

Front Oncol. 2022 ;12:863057

TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer.

Lecuelle J, Boidot R, Mananet H, Derangère V, Albuisson J, Goussot V, Arnould L, Tharin Z, Ray Coquard I, Ghiringhelli F, Truntzer C, Fumet JD

Cancers (Basel). 2021 Aug 31;13(17):

Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?

Niogret J, Dalens L, Truntzer C, Chevrier S, Favier L, Lagrange A, Coudert B, Fraisse C, Foucher P, Zouak A, Westeel V, Goussot V, Dérangère V, Albuisson J, Arnould L, Boidot R, Kaderbhai CG, Ghiringhelli F

Lung Cancer. 2021 Aug 29;161:98-107

Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.

Lauret Marie Joseph E, Kirilovsky A, Lecoester B, El Sissy C, Boullerot L, Rangan L, Marguier A, Tochet F, Dosset M, Boustani J, Ravel P, Boidot R, Spehner L, Haicheur-Adjouri N, Marliot F, Pallandre JR, Bonnefoy F, Scripcariu V, Van den Eynde M, Cornillot E, Mirjolet C, Pages F, Adotevi O

J Immunother Cancer. 2021 Jul;9(7):

Impact of proton therapy on antitumor immune response.

Mirjolet C, Nicol A, Limagne E, Mura C, Richard C, Morgand V, Rousseau M, Boidot R, Ghiringhelli F, Noel G, Burckel H

Sci Rep. 2021 Jun 29;11(1):13444

An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers.

Chevrier S, Richard C, Collot T, Mananet H, Arnould L, Boidot R

Cancers (Basel). 2021 Jun 22;13(13):

Superficial CD34-Positive Fibroblastic Tumor and PRDM10-rearranged Soft Tissue tumor are overlapping entities: a comprehensive study of 20 cases.

Perret R, Michal M, Carr RA, Velasco V, Švajdler M, Karanian M, Meurgey A, Paindavoine S, Soubeyran I, Coindre JM, Boidot R, Charon-Barra C, Geneste D, Weingertner N, Pissaloux D, Tirode F, Baud J, Le Loarer F

Histopathology. 2021 Jun 14;:

Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations.

Bergeron A, MacGrogan G, Bertaut A, Ladoire S, Arveux P, Desmoulins I, Bonnefoi H, Loustalot C, Auriol S, Beltjens F, Degrolard-Courcet E, Charon-Barra C, Richard C, Boidot R, Arnould L

Mod Pathol. 2021 Mar 22;:

Incidental findings in a series of 2500 gene panel tests for a genetic predisposition to cancer: Results and Impact on patients.

Nambot S, Bertolone G, Sawka C, Cosset E, Goussot V, Derangère V, Boidot R, Baurand A, Robert M, Coutant C, Loustalot C, Thauvin-Robinet C, Ghiringhelli F, Lançon A, Populaire C, Damette A, Collonge-Rame MA, Meunier-Beillard N, Lejeune C, Albuisson J, Faivre L

Eur J Med Genet. 2021 Mar 19;:104196

ER-/PR+ breast cancer: a distinct entity, which is morphologically and molecularly close to triple-negative breast cancer.

Beltjens F, Molly D, Bertaut A, Richard C, Desmoulins I, Loustalot C, Charon-Barra C, Courcet E, Bergeron A, Ladoire S, Jankowski C, Boidot R, Arnould L

Int J Cancer. 2021 Feb 26;:

The tumor microenvironment impairs Th1 IFNγ secretion through alternative splicing modifications of Irf1 pre-mRNA.

Bernard A, Hibos C, Richard C, Viltard E, Chevrier S, Lemoine S, Melin J, Humblin E, Mary R, Accogli T, Chalmin F, Bruchard M, Peixoto P, Hervouet E, Apetoh L, Ghiringhelli F, Vegran F, Boidot R

Cancer Immunol Res. 2021 Jan 8;:

PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.

Collot T, Niogret J, Carnet M, Chevrier S, Humblin E, Favier L, Bengrine-Lefevre L, Desmoulins I, Arnould L, Boidot R

Mol Med Rep. 2021 Jan;23(1):

and impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response.

Laurent PA, Kownacka A, Boidot R, Richard C, Limagne E, Morgand V, Froidurot L, Bonin C, Aubignac L, Ghiringhelli F, Créhange G, Mirjolet C

Clin Transl Radiat Oncol. 2020 Sep;24:116-122

Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage.

Fluckiger A, Daillère R, Sassi M, Sixt BS, Liu P, Loos F, Richard C, Rabu C, Alou MT, Goubet AG, Lemaitre F, Ferrere G, Derosa L, Duong CPM, Messaoudene M, Gagné A, Joubert P, De Sordi L, Debarbieux L, Simon S, Scarlata CM, Ayyoub M, Palermo B, Facciolo F, Boidot R, Wheeler R, Boneca IG, Sztupinszki Z, Papp K, Csabai I, Pasolli E, Segata N, Lopez-Otin C, Szallasi Z, Andre F, Iebba V, Quiniou V, Klatzmann D, Boukhalil J, Khelaifia S, Raoult D, Albiges L, Escudier B, Eggermont A, Mami-Chouaib F, Nistico P, Ghiringhelli F, Routy B, Labarrière N, Cattoir V, Kroemer G, Zitvogel L

Science. 2020 Aug 21;369(6506):936-942

Long-term response to Olaparib in carcinomatous meningitis of a mutated ovarian cancer: A case report.

Favier L, Truc G, Boidot R, Bengrine-Lefevre L

Mol Clin Oncol. 2020 Jul;13(1):73-75

An exceptional metaplastic lobular breast carcinoma diagnosed through exome sequencing.

Bergeron A, Desmoulins I, Beltjens F, Causeret S, Charon-Barra C, Martin E, Richard C, Boidot R, Arnould L

J. Clin. Pathol.. 2020 Jan 24;:

Implementation and use of whole exome sequencing in daily practice for metastatic solid cancer.

Réda M, Richard C, Bertaut A, Niogret J, Collot T, Fumet JD, Blanc J, Truntzer C, Desmoulins I, Ladoire S, Hennequin A, Favier L, Bengrine L, Vincent J, Hervieu A, Dusserre JG, Lepage C, Foucher P, Borg C, Albuisson J, Arnould L, Nambot S, Faivre L, Boidot R, Ghiringhelli F

EBioMedicine. 2020 Jan 7;51:102624

Solid-type adenoid cystic carcinoma of the breast, a distinct molecular entity enriched in NOTCH and CREBBP mutations.

Massé J, Truntzer C, Boidot R, Khalifa E, Pérot G, Velasco V, Mayeur L, Billerey-Larmonier C, Blanchard L, Charitansky H, Soubeyran I, Iggo R, Arnould L, MacGrogan G

Mod. Pathol.. 2019 Dec 19;:

Titanate Nanotubes Engineered with Gold Nanoparticles and Docetaxel to Enhance Radiotherapy on Xenografted Prostate Tumors.

Loiseau A, Boudon J, Oudot A, Moreau M, Boidot R, Chassagnon R, Saïd NM, Roux S, Mirjolet C, Millot N

Cancers (Basel). 2019 Dec 6;11(12):

Cleaved Caspase-3 transcriptionally regulates angiogenesis promoting chemotherapy resistance.

Bernard A, Chevrier S, Beltjens F, Dosset M, Viltard E, Lagrange A, Dérangère V, Oudot A, Ghiringhelli F, Collin B, Apetoh L, Feron O, Chen S, Arnould L, Végran F, Boidot R

Cancer Res.. 2019 Oct 14;:

Somatic substitution signature as an innovative tool in lung cancer diagnosis.

Busca S, Salleron J, Boidot R, Merlin JL, Harlé A

Sci Rep. 2019 Oct 10;9(1):14561

CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin.

Galaine J, Turco C, Vauchy C, Royer B, Mercier-Letondal P, Queiroz L, Loyon R, Mouget V, Boidot R, Laheurte C, Lakkis Z, Jary M, Adotévi O, Borg C, Godet Y

Int. J. Cancer. 2019 Aug 9;:

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.

Grapin M, Richard C, Limagne E, Boidot R, Morgand V, Bertaut A, Derangere V, Laurent PA, Thibaudin M, Fumet JD, Crehange G, Ghiringhelli F, Mirjolet C

J Immunother Cancer. 2019 Jun 25;7(1):160

Healthy adiposity and extended lifespan in obese mice fed a diet supplemented with a polyphenol-rich plant extract.

Aires V, Labbé J, Deckert V, Pais de Barros JP, Boidot R, Haumont M, Maquart G, Le Guern N, Masson D, Prost-Camus E, Prost M, Lagrost L

Sci Rep. 2019 Jun 24;9(1):9134

Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase 2 study.

Toulmonde M, Bellera CA, Blay JY, Bouche O, Mir O, Penel N, Isambert N, Duffaud F, Esnaud T, Boidot R, Geneste D, Ghiringhelli F, Lucchesi C, Le Loarer F, Italiano A

Clin. Cancer Res.. 2019 Apr 12;:

RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer.

Ledys F, Klopfenstein Q, Truntzer C, Arnould L, Vincent J, Bengrine L, Remark R, Boidot R, Ladoire S, Ghiringhelli F, Derangere V

J Immunother Cancer. 2018 Nov 19;6(1):123

Transcriptome-wide identification of transient RNA G-quadruplexes in human cells.

Yang SY, Lejault P, Chevrier S, Boidot R, Robertson AG, Wong JMY, Monchaud D

Nat Commun. 2018 Nov 9;9(1):4730

Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment.

Vrecko S, Guenat D, Mercier-Letondal P, Faucheu H, Dosset M, Royer B, Galaine J, Boidot R, Kim S, Jary M, Adotévi O, Borg C, Godet Y

Oncotarget. 2018 Oct 23;9(83):35394-35407

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.

Fumet JD, Richard C, Ledys F, Klopfenstein Q, Joubert P, Routy B, Truntzer C, Gagné A, Hamel MA, Guimaraes CF, Coudert B, Arnould L, Favier L, Lagrange A, Ladoire S, Saintigny P, Ortiz-Cuaran S, Perol M, Foucher P, Hofman P, Ilie M, Chevrier S, Boidot R, Derangere V, Ghiringhelli F

Br. J. Cancer. 2018 Oct 15;:

Exome analysis reveals genomic markers associated with better efficacy of nivolumab in lung cancer patients.

Richard C, Fumet JD, Chevrier S, Derangère V, Ledys F, Lagrange A, Favier L, Coudert B, Arnould L, Truntzer C, Boidot R, Ghiringhelli F

Clin. Cancer Res.. 2018 Aug 28;:

Secondary findings from whole-exome/genome sequencing evaluating stakeholder perspectives. A review of the literature.

Delanne J, Nambot S, Chassagne A, Putois O, Pelissier A, Peyron C, Gautier E, Thevenon J, Cretin E, Bruel AL, Goussot V, Ghiringhelli F, Boidot R, Tran-Mau-Them F, Philippe C, Vitobello A, Demougeot L, Vernin C, Lapointe AS, Bardou M, Luu M, Binquet C, Lejeune C, Joly L, Juif C, Baurand A, Sawka C, Bertolone G, Duffourd Y, Sanlaville D, Pujol P, Geneviève D, Houdayer F, Thauvin-Robinet C, Faivre L

Eur J Med Genet. 2018 Aug 27;:

Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L.

Niogret J, Coudert B, Boidot R

J Thorac Oncol. 2018 Jul;13(7):e113

Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases.

Alsadoun N, MacGrogan G, Truntzer C, Lacroix-Triki M, Bedgedjian I, Koeb MH, El Alam E, Medioni D, Parent M, Wuithier P, Robert I, Boidot R, Arnould L

Mod. Pathol.. 2018 May 21;:

amplification induces sensitivity to anti therapy in pancreatic acinar cell carcinoma.

Richard C, Niogret J, Boidot R, Ghiringhelli F

World J Gastrointest Oncol. 2018 Apr 15;10(4):103-107

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.

Dosset M, Vargas TR, Lagrange A, Boidot R, Végran F, Roussey A, Chalmin F, Dondaine L, Paul C, Marie-Joseph EL, Martin F, Ryffel B, Borg C, Adotévi O, Ghiringhelli F, Apetoh L

Oncoimmunology. 2018 ;7(6):e1433981

IRF8-dependent molecular complexes control the Th9 transcriptional program.

Humblin E, Thibaudin M, Chalmin F, Derangère V, Limagne E, Richard C, Flavell RA, Chevrier S, Ladoire S, Berger H, Boidot R, Apetoh L, Végran F, Ghiringhelli F

Nat Commun. 2017 Dec 12;8(1):2085

Antibiotic Use Does Not Appear to Influence Response to Nivolumab.

Kaderbhai C, Richard C, Fumet JD, Aarnink A, Foucher P, Coudert B, Favier L, Lagrange A, Limagne E, Boidot R, Ghiringhelli F

Anticancer Res.. 2017 06;37(6):3195-3200

DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues.

Glorian V, Allègre J, Berthelet J, Dumetier B, Boutanquoi PM, Droin N, Kayaci C, Cartier J, Gemble S, Marcion G, Gonzalez D, Boidot R, Garrido C, Michaud O, Solary E, Dubrez L

Cell Death Dis. 2017 May;8(5):e2816

Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A0201/DRB10101 transgenic mice.

Rangan L, Galaine J, Boidot R, Hamieh M, Dosset M, Francoual J, Beziaud L, Pallandre JR, Marie Joseph EL, Asgarova A, Borg C, Saati TA, Godet Y, Latouche JB, Valmary-Degano S, Adotévi O

Oncotarget. 2017 Apr;:

Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation.

Limagne E, Thibaudin M, Euvrard R, Berger H, Chalons P, Végan F, Humblin E, Boidot R, Rébé C, Derangère V, Ladoire S, Apetoh L, Delmas D, Ghiringhelli F

Cell Rep. 2017 Apr;19(4):746-759

Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model.

Mirjolet C, Boudon J, Loiseau A, Chevrier S, Boidot R, Oudot A, Collin B, Martin E, Joy PA, Millot N, Créhange G

Int J Nanomedicine. 2017 ;12:6357-6364

Immune classifications with cytotoxic CD8(+) and Th17 infiltrates are predictors of clinical prognosis in glioblastoma.

Madkouri R, Kaderbhai CG, Bertaut A, Truntzer C, Vincent J, Aubriot-Lorton MH, Farah W, Limagne E, Ladoire S, Boidot R, Derangère V, Ghiringhelli F

Oncoimmunology. 2017 ;6(6):e1321186

Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer.

Kaderbhai CG, Richard C, Fumet JD, Aarnink A, Ortiz-Cuaran S, Pérol M, Foucher P, Coudert B, Favier L, Lagrange A, Limagne E, Boidot R, Ladoire S, Poudenx M, Ilie M, Hofman P, Saintigny P, Ghiringhelli F

Oncoimmunology. 2017 ;6(9):e1339856

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?

Eliade M, Skrzypski J, Baurand A, Jacquot C, Bertolone G, Loustalot C, Coutant C, Guy F, Fumoleau P, Duffourd Y, Arnould L, Delignette A, Padéano MM, Lepage C, Raichon-Patru G, Boudrant A, Bône-Lépinoy MC, Villing AL, Charpin A, Peignaux K, Chevrier S, Vegran F, Ghiringhelli F, Boidot R, Sevenet N, Lizard S, Faivre L

Oncotarget. 2017 Jan;8(2):1957-1971

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.

Ghiringhelli F, Richard C, Chevrier S, Végran F, Boidot R

World J. Gastroenterol.. 2016 Dec;22(48):10680-10686

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma.

Bertaut A, Truntzer C, Madkouri R, Kaderbhai CG, Derangère V, Vincent J, Chauffert B, Aubriot-Lorton MH, Farah W, Mourier KL, Boidot R, Ghiringhelli F

Oncotarget. 2016 Oct;7(43):70948-70958

Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen.

Limagne E, Euvrard R, Thibaudin M, Rébé C, Derangère V, Chevriaux A, Boidot R, Végran F, Bonnefoy N, Vincent J, Bengrine-Lefevre L, Ladoire S, Delmas D, Apetoh L, Ghiringhelli F

Cancer Res.. 2016 Sep;76(18):5241-52

Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells.

Galaine J, Kellermann G, Guillaume Y, Boidot R, Picard E, Loyon R, Queiroz L, Boullerot L, Beziaud L, Jary M, Mansi L, André C, Lethier L, Ségal-Bendirdjian E, Borg C, Godet Y, Adotévi O

J. Immunol.. 2016 Sep;197(5):1597-608

Rare RAS Mutations in Metastatic Colorectal Cancer Detected During Routine RAS Genotyping Using Next Generation Sequencing.

Harlé A, Filhine-Tresarrieu P, Husson M, Boidot R, Rouyer M, Dubois C, Leroux A, Merlin JL

Target Oncol. 2016 Jun;11(3):363-70

Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer.

Kaderbhai CG, Boidot R, Beltjens F, Chevrier S, Arnould L, Favier L, Lagrange A, Coudert B, Ghiringhelli F

Oncotarget. 2016 Apr;7(17):24860-70

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?

Derangère V, Fumet JD, Boidot R, Bengrine L, Limagne E, Chevriaux A, Vincent J, Ladoire S, Apetoh L, Rébé C, Ghiringhelli F

Oncotarget. 2016 Feb;7(8):9309-21

Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients.

Hennequin A, Derangère V, Boidot R, Apetoh L, Vincent J, Orry D, Fraisse J, Causeret S, Martin F, Arnould L, Beltjens F, Ghiringhelli F, Ladoire S

Oncoimmunology. 2016 Feb;5(2):e1054598

Liver X receptor ligand cytotoxicity in colon cancer cells and not in normal colon epithelial cells depends on LXRbeta subcellular localization.

Courtaut F, Derangere V, Chevriaux A, Ladoire S, Cotte AK, Arnould L, Boidot R, Rialland M, Ghiringhelli F, Rebe C

Oncotarget. 2015 Sep 29;6(29):26651-62

Transcriptome analysis of TH2 CD4(+) T cells differentiated from wild-type and NLRP3KO mice.

Bruchard M, Boidot R, Ghiringhelli F, Vegran F

Genom Data. 2015 Jul 9;5:314-5

The receptor NLRP3 is a transcriptional regulator of TH2 differentiation.

Bruchard M, Rebe C, Derangere V, Togbe D, Ryffel B, Boidot R, Humblin E, Hamman A, Chalmin F, Berger H, Chevriaux A, Limagne E, Apetoh L, Vegran F, Ghiringhelli F

Nat Immunol. 2015 Aug;16(8):859-70